Inclisiran Shows Promise for Treating High Cholesterol in Children

This commentary examines the potential use of inclisiran in children with familial hypercholesterolemia, a genetic condition causing severely elevated cholesterol levels from birth. Without treatment, these children face dramatically increased risks of heart disease and stroke in early adulthood.

Inclisiran is a revolutionary cholesterol medication that works by silencing genes responsible for cholesterol production. Unlike daily statins, it requires only two injections per year while maintaining consistent cholesterol reduction. The drug has proven highly effective in adults, reducing LDL cholesterol by 50% or more.

The authors discuss whether extending inclisiran use to pediatric populations could transform outcomes for children with genetic high cholesterol. Early aggressive treatment during childhood may prevent arterial damage that begins accumulating from birth in these patients. The twice-yearly dosing could also improve treatment adherence compared to daily medications.

For longevity and health optimization, this represents a paradigm shift toward preventing cardiovascular disease decades before symptoms appear. Children treated early with effective cholesterol management may avoid the heart attacks and strokes that typically occur in their 30s and 40s without intervention.

However, questions remain about long-term safety in developing children and optimal treatment protocols. The commentary weighs these considerations against the clear benefits of preventing early cardiovascular disease in this high-risk population.